Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

Bavituximab is a monoclonal antibody that targets phosphatidylserine in the presence of β2 glycoprotein 1 (β2GP1) to exert an antitumor immune response. This phase III trial determined the efficacy of bavituximab combined with docetaxel in patients with previously treated advanced non-small-cell lun...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2018-07, Vol.29 (7), p.1548-1553
Hauptverfasser:	Gerber, D.E., Horn, L., Boyer, M., Sanborn, R., Natale, R., Palmero, R., Bidoli, P., Bondarenko, I., Germonpre, P., Ghizdavescu, D., Kotsakis, A., Lena, H., Losonczy, G., Park, K., Su, W -C, Tang, M., Lai, J., Kallinteris, N.L., Shan, J.S., Reck, M., Spigel, D.R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - pathology Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage antibody Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology chemotherapy Docetaxel - administration & dosage Double-Blind Method Editor's Choice Female Follow-Up Studies Humans immunotherapy Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Middle Aged Original phosphatidylserine Prognosis Prospective Studies Salvage Therapy Survival Rate vascular
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!